Investors & Media

Release Details

Poseida Therapeutics, Inc. Announces Worldwide License Agreement With Janssen to Apply Centyrin Technology in the Development of Chimeric Antigen Receptor (CAR) Therapies

SAN DIEGO, Aug. 11, 2015 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (Poseida), a private biotechnology company spun out of Transposagen Biopharmaceuticals, Inc. (Transposagen), and headquartered in San Diego, CA, today announced they have entered into a worldwide License Agreement with Janssen Biotech, Inc. (Janssen) to research, develop, manufacture and commercialize licensed products using Janssen Centyrin technology.

Centyrins are a class of Janssen proprietary alternative scaffold molecules that can be engineered to bind to target proteins with an interface of similar size to those used by antibodies. Critical to the use of Centyrins to treat human disease, Janssen has developed a number of Centyrin libraries that are used for in vitro selection of Centyrin molecules that bind to protein targets with high affinity and specificity.

Poseida has entered into an exclusive license to use Centyrins to develop pharmaceutical products containing or comprised of autologous T-cells or any NK- or NK-like cells expressing a Centyrin molecule or Centyrin Chimeric Antigen Receptor (CAR) molecule.  CAR therapies have shown promise in early human clinical trials for the treatment of blood cancers. As part of the Centyrin license, Poseida will gain access to Centyrin molecules against three existing targets, including one that Poseida  is developing in house as part of an autologous CAR-T therapy to treat multiple myeloma.

Under the License Agreement, Poseida gains the rights to screen the Centyrin library to identify and develop Centyrin molecules against new cancer antigens that Poseida identifies or licenses, including solid tumor antigens. Poseida will pay Janssen an undisclosed upfront fee and potential development, regulatory, and commercial milestone payments. 

“This License Agreement further strengthens our existing synergistic drug development collaboration and grants Poseida access to a powerful Janssen platform. The Centyrin technology can be used to develop binding molecules to numerous cancer antigens and paves the way towards cutting-edge CAR-based immuno-oncology therapeutics, which may eventually treat many different cancers that currently have unsatisfactory treatment options,” said Eric Ostertag, CEO of Poseida.

About Poseida

Poseida is a therapeutics-focused biotechnology company using best-in-class gene editing technologies to develop novel, life-saving therapies, including gene therapy for orphan liver diseases and immuno-oncology therapeutics for several types of cancer.  Poseida owns several industry-leading gene editing technologies, including the piggyBacTM DNA Modification System, XTNTM TALEN and NextGENTM CRISPR site-specific nucleases, and Footprint-FreeTM Gene Editing (FFGE). FFGE is the cleanest gene editing technology that is commercially available, allowing for surgically-precise changes of as little as a single nucleotide in any genome without unwanted mutations and with the ability to select for otherwise rare events.


Johanna Mylet